Calliditas announces acquisition of remaining Genkyotex minority shares
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company now controls 100% of the share capital of Genkyotex SA (“Genkyotex”), after the completion of a centralized squeeze out offer to all minority shareholders.Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in